Somatic mutations occurring in tumor cells can lead to the generation of novel TSA, which potentially can be recognized as non-self, referred to as neoantigens, which may be presented as tumor-specific peptides by major histocompatibility complex (MHC) molecules on the tumor cell surface. The gene discussed is HLA-C; the disease is neoplasm.